Royaume-Uni-St Asaph: Kits de diagnostic
Avis de préinformation
Le présent avis est un avis de préinformation uniquement
Section I: Pouvoir adjudicateur
Adresse principale: http://www.procurement.wales.nhs.uk
Adresse du profil d’acheteur: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221
Adresse principale: http://www.resah.fr/
Assistance Publique-Hospitaux de Paris, France
CGS UniHA, France
Societa Regionale per la Sanita, Italy
Reseau des acheteurs hospitaliers, France
Section II: Objet
Hospital Acquired Respiratory Infections (ICU) including Ventilator Associated Pneumonia (VAP)
Suppliers who are able to offer any solution, either in part or in full, to diagnose VAP earlier than current culture methods; or offer solutions which may push the boundaries of innovation to prevent VAP infections are invited to register their interest.
NHS Wales Shared Services Partnership (NWSSP), hosted by Velindre NHS Trust, is publishing this prior information notice (PIN) on behalf of the European wide Innovative Procurement of Health and care Innovation (EURIPHI) project. EURIPHI is a consortium of 25 leading organisations in procurement and health care from across Europe created as a result of EU Coordination and Support Action (CSA) under Horizon 2020 ‘Innovation in Healthcare’. The aim of the project is to create a Europe-wide consortium which will define unmet needs in order to implement innovation and integrated solutions through a value-based procurement approach.
The purpose of this PIN is to open communication between the EURIPHI consortium and the market in relation to Hospital Acquired Respiratory Infections within ICU, specifically Ventilator Associated Pneumonia (VAP).
VAP is defined as pneumonia that occurs more than 48 hours after intubation. Its diagnosis is based on clinical signs and symptoms such as new infiltrate on the chest X-ray. Culture-based identification of the causative pathogen is slow and often only confirms an initial diagnosis and might guide antibiotic treatment.
Earlier detection of the presence of pathogens and their antibiotic resistance/susceptibility may assist in appropriate treatment being administered more rapidly thus positively impacting on recovery times; mortality rates; length of stay; reduction in overall costs and better antibiotic stewardship.
Further, prevention to detect VAP earlier, e.g. before suspected; or avoid VAP infections would improve perceived benefits.
Suppliers who are able to offer any solution, either in part or in full, to diagnose VAP earlier than current culture methods; or offer solutions which may push the boundaries of innovation to prevent VAP infections are invited to register their interest with NHS Wales in order to enter into open market consultation with the EURIPHI consortium.
Interested parties are requested to complete the attached short questionnaire and return to Joanne Liddle, Senior Category Manager, NWSSP by email to Joanne.email@example.com and include contact name; company name; telephone number and contact email address.
Please note publication of this PIN is a follow up to original open market consultation held by EURIPHI in Paris in 2019 as part of this project. This PIN does not guarantee a procurement exercise will follow as this will be subject to funding of individual health organisations.
We wish to enter into discussions with interested suppliers during January and February 2020, interested suppliers are asked to ensure their interest is registered by no later than 10.1.2020.
Section IV: Procédure
Section VI: Renseignements complémentaires
Note: to register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=97691